Ruesch Center | Georgetown University

Gastrointestinal (GI) Cancers are the most common and most fatal of all cancers. The Ruesch Center will re-focus national efforts on curing this deadly set of diseases.

Logo of the Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center. This logo has four blue boxes and text.

Meet Ruesch Center Director:
John L. Marshall, MD

Connect With Us Via

Tweets by RueschCenter

Recent News

Current Role of Chemotherapy in GI and Colorectal Cancer
August 15, 2018
John L. Marshall, MD, discusses the use of chemotherapy in patients with colorectal (CRC) or other gastrointestinal (GI) cancers
Liver Cancer Deaths Rise, Along with Hope for Better Treatments
July 27, 2018
Aiwu Ruth He, MD, PhD, an associate professor at Georgetown Lombardi Comprehensive Cancer Center, is working with colleagues on research into ways to stem rising liver cancer death rates.
The Rising Incidence of Early-Onset CRC: What Do We Know and What Can We Do?
July 24, 2018
During an OncLive Peer Exchange® program on individualizing treatment and improving outcomes for patients with CRC, a panel of experts shared their insights on early-onset CRC, which has been observed to occur as early as adolescence.
Advanced Pancreatic Cancer: The Road to Personalized Care
July 24, 2018
In this OncLive® Peer Exchange®, an amazing panel of experts in the field of gastrointestinal oncology provide you with a perspective on recent pancreatic cancer advances and what they mean to the care of your patients for weeks ahead.
OncLive® and The Ruesch Center to Host the Second Annual Luminary Awards in GI Cancers
July 9, 2018
The awards honor individuals who are making a difference in the gastrointestinal cancers community.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
July 5, 2018
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating Pancreatic Cancer patients with certain genetic mutations.
Experts Anticipate a Growing Menu of Frontline Options in Liver Cancer
July 4, 2018
Panelists review data for lenvatinib (Lenvima), and novel drugs under investigation in the second line for HCC, such as cabozantinib (Cabometyx/Cometriq) and pembrolizumab (Keytruda).
Marshall Makes the Case for Molecular Sorting in Gastrointestinal Disease
July 3, 2018
Oncologists have been slow to introduce targeted and immune therapies into the treatment of gastrointestinal cancers, but that is changing, and poor patient survival statistics call for a continuation of this trend.